WO2004067037A1 - 経口腸内環境調整剤および経口正常腸内細菌叢育成キット - Google Patents
経口腸内環境調整剤および経口正常腸内細菌叢育成キット Download PDFInfo
- Publication number
- WO2004067037A1 WO2004067037A1 PCT/JP2004/000798 JP2004000798W WO2004067037A1 WO 2004067037 A1 WO2004067037 A1 WO 2004067037A1 JP 2004000798 W JP2004000798 W JP 2004000798W WO 2004067037 A1 WO2004067037 A1 WO 2004067037A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- intestinal
- useful
- oral
- bacteria
- environment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Oral intestinal environment regulator and oral normal intestinal flora growth kit
- the present invention relates to an oral composition for promoting the growth of useful bacteria in the intestine, suppressing the growth of harmful bacteria, and normalizing the intestinal bacterial flora. Everybody's art
- Intestinal bacteria include useful bacteria, which are so-called good bacteria, and harmful bacteria, which are bad bacteria. It is important that useful bacteria maintain a dominant bacterial flora. Useful bacteria have a cholesterol lowering effect, an antitumor effect, an immunopotentiating effect, an inhibitory effect on H. pylori, and the like. Yogurt, which has long been edible, has the effect of increasing and maintaining useful intestinal bacteria. In recent years, newly developed lactic acid bacteria, bifidobacteria, and the like have been taken in for the purpose of further growing useful bacteria, utilizing their own functions as useful bacteria.
- the gut flora is also involved in diabetes, hyperlipidemia, hypertension, and obesity, which have been termed lifestyle diseases from the name adult disease.
- Lifestyle-related diseases are caused by unfavorable lifestyle such as unbalanced eating, overeating, excessive consumption of alcoholic beverages, smoking, and lack of exercise.
- Its lifestyle makes it difficult for good bacteria to live in, and creates an intestinal environment where bad bacteria can easily spread, and the increase in harmful bacteria causes liver damage, gastrointestinal disorders, arteriosclerosis, high blood pressure, cancer, and aging.
- it is difficult to reliably improve and maintain the balance of the intestinal flora simply by taking a useful bacterium and its growth promoter in order to create and maintain the intestinal flora dominating the useful bacteria. Disclosure of the invention
- An object of the present invention is to provide an oral intestinal environment regulator and an oral normal intestinal flora growing kit suitable for improving intestinal bacterial flora.
- the present inventors have found that taking an oral intestinal cleaning agent, which has been used for the purpose of eliminating intestinal contents before colonoscopy or colorectal surgery, temporarily reduces harmful bacteria colonized in the intestine. It has been found that the intestinal environment suitable for colonization of useful bacteria and suppressing the growth of harmful bacteria can be prepared. In addition, after preparing such intestinal environment and ingesting useful bacteria such as lactic acid bacteria, the intestinal flora, which is predominantly useful, can be prepared, and an intestinal useful bacteria growth promoter such as dietary fiber can be used. We found that the combination was more effective and completed the present invention.
- the present invention provides an oral intestinal environment control for eliminating intestinal harmful bacteria and adjusting the growth environment of useful bacteria, which comprises a colloid osmotic pressure adjusting agent and / or a crystalline osmotic pressure adjusting agent.
- agent a colloid osmotic pressure adjusting agent and / or a crystalline osmotic pressure adjusting agent.
- the oral intestinal environment-regulating agent of the present invention promotes excretion of intestinal contents in humans in which harmful bacteria are predominant, reduces harmful bacteria, and prepares an environment suitable for growth of useful bacteria.
- the oncotic pressure regulator contained in the oral intestinal environment regulator of the present invention includes indigestible dextrin, polyethylene glycol, polydextros, dextran dextrin, hydroxyethyl starch, acacia, pullulan, pectin carboxymethylcellulose. , Can be mentioned.
- a polymer selected from the group consisting of polyethylene glycol, polydextrose, dextran, hydroxyethyl cellulose, gum arabic, pullulan and pectin is contained as an osmotic pressure adjusting agent.
- indigestible dextrin is superior in that it has better stability than polyethylene glycol, is easy to take, and can be freely combined with additives such as fragrances. It is also excellent because it has few side effects such as diarrhea even when ingested in large quantities and has extremely low calories.
- an electrolyte or a mixture of an electrolyte and a saccharide is used as the crystalline osmotic pressure adjusting agent contained in the oral intestinal environment adjusting agent of the present invention.
- the electrolyte refers to a substance to be I O emissions dissociated in solution, N a +, K +, C a w, M g C 1 ⁇ HC 0 3 ⁇ S 0 4 -, HP o 4 - ⁇ organic acid And organic bases. More specifically, the same compounds as those used for intravenous electrolyte infusion and the like can be used. Sodium chloride, sodium acetate, sodium citrate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium sulfate, sodium lactate, etc.
- potassium sources Dihydrogen phosphate phosphate, hydrogen phosphate phosphate, sulfuric acid, lactic acid, etc.
- the sources of calcium include calcium chloride, calcium dalconate, calcium pantothenate, calcium lactate, calcium acetate, and glycerose. Calcium phosphate, etc .;
- Magnesium sources magnesium sulfate, magnesium chloride, magnesium acetate, magnesium citrate, etc .;
- Phosphorus sources sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium glycerophosphate, etc.
- Examples of the chlorine source include sodium chloride, potassium chloride, calcium chloride, and magnesium chloride
- examples of the bicarbonate ion source include sodium hydrogencarbonate. These compounds are in the form of hydrates. Is also good.
- the sugars mixed with the electrolyte include sugars as well as sugar alcohols. Specific examples include sorbitol, xylitol, erythritol, mannitol, trehalose, lactitol, lactulose, maltitol, palatinose, raffinose, and glycerin. In particular, xylitol, sorbitol, lactulose, lactitol, and raffinose are preferred.
- the above-mentioned oncotic agent and crystalline osmotic agent are important components for minimizing fluctuations in serum electrolyte balance and osmotic pressure in a living body.
- an osmotic pressure adjusting agent a colloidal osmotic pressure adjusting agent, a crystalline osmotic pressure adjusting agent, or both are blended and used.
- the amount is adjusted depending on the condition of the patient, the amount of intestinal residue, and the like, but it is preferably dissolved in water and used as an aqueous solution having an osmotic pressure of 200 to 44 m0sm / L. More preferably, the type and amount of each component should be selected so that they can be adjusted to an isotonicity of 280 to 32 OmOsmZL or an osmotic pressure range close to isotonicity.
- the amount of the oncotic agent used is 5 to 100 grams, preferably 10 to 60 grams, in a formulation that dissolves in 1 liter of water.
- raw ion such as magnesium ion or sulfate ion
- magnesium ion adjust to 40 to 120 mEq / L when the oral intestinal environment regulator is dissolved in water.
- concentration is adjusted to 40 to 120 mEq / L.
- the amount used is 5 to 80 g, preferably 10 to 60 g, in a formulation dissolved in 1 liter of water.
- a preferable formulation is a mixture of a colloid osmotic pressure regulator and an electrolyte, a mixture of an electrolyte and a saccharide as a crystal osmotic pressure modifier, or an indigestible dextrin as a colloid osmotic pressure modifier and an electrolyte as a crystalline osmotic pressure modifier. It is a mixture of sugars.
- N a + is 3 0 ⁇ 1 5 0 mEq / L
- K + is 3 ⁇ 2 0mEq / L
- C 1- 2 0-7 0 Contains electrolytes so that mEq / L and HCO are 10 to 50 mEq / L, indigestible dextrin, polyethylene glycol, polydextros, dextran, dextrin, hydroxyshecil starch, gum arabic, pullulan, ⁇ Kuching, Albumin, Carboki
- At least one oncotic agent selected from the group consisting of cimethylcellulose and / or sorbitol, xylitol, erythritol, mannitol, trehalose, lactitol, lactulose, maltitol, palatinose, raffinose, glycerin
- at least one saccharide selected from the group consisting of In particular, the use of indigestible dextrin, polyethylene
- Indigestible dextrins are superior to sugars as crystalline osmotic pressure regulators in that they have lower calories and are less likely to cause diarrhea. However, if the total amount per 1 L exceeds 30 g, the solubility may be insufficient. Therefore, it is preferable to combine with a saccharide as a crystalline osmotic pressure regulator. In that case, the total amount (weight ratio) of the indigestible dextrin Z saccharide is preferably in the range of 0.7 to 4, and particularly preferably in the range of 1.5 to 3.
- Indigestible dextrin is a water-soluble dietary fiber prepared by hydrolyzing heat-treated starch with amylase and separating indigestible components from undegraded products. Indigestible dextrin is marketed by Matsutani Chemical Industry Co., Ltd., for example, under the trade names Pine Fiber-1, Fiber-1sol2, Fiber-1sol2H, and the like.
- the colloid osmotic pressure adjusting agent and / or the crystalline osmotic pressure adjusting agent contained in the oral intestinal environment adjusting agent of the present invention are adjusted in particle size so that they can be mixed, and then filled into an airtight container. Preferably it is sealed. Adjusting the contents so that one package is used after dissolving it in 25 OmL or 1 L or 2 L of water is suitable for the intended use.
- a useful intestinal bacterial growth promoter can be added to the oral intestinal environment regulator. Addition of a useful intestinal bacterial growth promoter helps intestinal washing and is effective in the early growth of useful bacteria. When an indigestible dextrin is used as the oncotic agent, it is particularly advantageous in that it also functions as a useful intestinal bacterial growth promoter.
- Another embodiment of the present invention is an oral normal intestinal bacterial flora growing kit in which one or both of a useful intestinal bacterial composition and a useful intestinal bacterial growth promoter are combined with the above-mentioned oral intestinal environmental regulator.
- the useful enteric bacteria composition and the useful enteric bacteria growth promoter are separately packaged and combined with the oral intestinal environment regulator.
- Intestinal useful bacteria composition and intestinal useful bacteria growth promoter Can be packaged separately or together.
- the intestinal useful bacteria growth promoter is a nutrient for useful bacteria, promotes the growth of useful bacteria, suppresses intestinal putrefaction, and suppresses the growth of harmful bacteria. Any substance that is effective for the growth of useful intestinal bacteria can be used. Dietary fiber adsorbs harmful substances generated in the intestinal tract, promotes defecation, and promotes the growth of intestinal bacteria. Indigestible saccharides are nutrient sources for useful bacteria. Yeasts, tannins, and the like can be used to promote the growth of useful bacteria. Short-chain fatty acids and organic acids other than fatty acids, such as lactic acid, dalconic acid, citric acid, and malic acid, suppress the growth of harmful bacteria and promote the growth of useful bacteria.
- any of a water-soluble fiber soluble in water and an insoluble fiber insoluble in water may be used.
- the water-soluble fibers include indigestible dextrin, pectin, methoxypectin, galactomannan, alginic acid and its salts, galactan such as tengusa and ogonori.
- water-insoluble fibers include fibers obtained from plants such as apple fiber and corn fiber, dried vegetables such as broccoli, cauliflower, cabbage, and spinach, cellulose, hemicellulose, carrageenan, Examples include soybeans and wheat bran containing lignin or the like as a constituent.
- the target daily intake of dietary fiber is between 20 and 25 grams. It is said that an average of 17 grams is consumed by food, so it is sufficient to supplement 5 to 15 grams, preferably 3 to 8 grams per day. More can be done in some cases.
- saccharides various indigestible saccharides such as xylitol, sorbitol, lactulose, palatinose, fructooligosaccharide, galactooligosaccharide, nectar oligosaccharide, raffinose, sucrose, and xylo-oligosaccharide are effective for the growth of useful bacteria.
- the short-chain fatty acid is a fatty acid having a carbon chain length of 2 to 5, and for example, acetic acid, propionic acid, butyric acid, and cabronic acid are preferred.
- yeast beer yeast And baker's yeast.
- tannins catechin, gallocatechin, epicatechin and the like are preferable.
- the amount of sugars, short-chain fatty acids, yeast, tannins, and other organic acids can be set as appropriate. 0.1 to 10 grams per day, preferably 0.5 to 5 grams per day, but can be higher in some cases.
- Useful bacteria used in the intestinal useful bacteria composition of the present invention include Bifidobacterium 'Bifidum, Bifidobacterium adrescentis, Bifidobacterium' breve, Bifidobacterium infateis, Bifidobacterium longum. Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus planum lamb, Lactobacillus delbrutsukii, Lactobacillus crispatas, Lactobacillus etc.
- Lactobacillus such as fermentam, Lactobacillus' reuteri, Lactobacillus zeae; Streptococcus such as Streptococcus thermophilus; Enterococcus Preferred are Enterococcus spp., Such as Hue squirrels, Enterococcus faecium, and Lactococcus spp., Such as Lactococcus' lactis.
- Bifidobacterium 'Bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus helveticus, Lactococcus lactis, Lactobacillus gasseri, Streptococca Saccharomyces, Lactobacillus casei, Lactobacillus acidophilus, Enterococcus hues, and Enterococcus are preferred.
- a flavoring agent, an auxiliary agent, a bulking agent, and the like can be added to the oral intestinal environment regulator, the useful intestinal bacterial composition, and the useful intestinal bacterial growth promoter, as long as the purpose is not impaired.
- a predetermined amount is dissolved in water to prepare a solution.
- 0.2-4 L, preferably 1-2 L, of this solution is taken orally.
- the dose is preferably at a rate of about 1 L per hour.
- intestinal contents are excreted.
- Average weekly bowel movements If you have less than 4 constipations, take 200 to 30 OmL of the dissolving solution continuously for 3 to 5 days to improve bowel movement, and then take 1-2 L orally for the purpose of improving bowel movement. It is therefore preferable to excrete intestinal contents.
- the number of doses of the oral intestinal environmental conditioner for excreting intestinal contents can be one to several times.
- the second dose should be one week to two months after the first dose.
- the useful enteric bacteria composition and the useful enteric bacteria growth promoter can be taken simultaneously with the oral intestinal environment regulator, but preferably the intestinal contents were excreted by taking the oral intestinal environment regulator. Later, it is desirable to take 1 to 3 times a day continuously. Take the first oral intestinal environment-regulating agent, and then take the useful enteric bacteria composition and the useful enteric bacteria growth promoter continuously for 1 week to 2 months. This cycle is defined as one cycle, and after the completion of one cycle, the same cycle is repeated according to the symptoms, whereby the intestinal flora is greatly improved to an environment where useful bacteria predominate.
- the useful enteric bacteria composition and the useful enteric bacteria growth promoter it is desirable to use the useful enteric bacteria composition and the useful enteric bacteria growth promoter in combination. However, for 1 week to 1 month after taking the oral intestinal environmental conditioner, use the intestinal useful bacterial composition and the intestinal useful bacterial growth promoter together, and then take only the intestinal useful bacterial growth promoter. You can also. Therefore, depending on the condition of the user, the package of one or both of the useful enteric bacteria composition and the useful enteric bacteria growth promoter, which is required until the next dose of the oral enteral environment modifier, It is preferable to combine it with one package of the oral intestinal environmental conditioner and house it in one package. Also, 3 to 5 small packages for 200 to 300 ml for improving bowel movement can be accommodated in the package.
- the oral intestinal environmental conditioner can also accommodate 2 to 20 pieces of the same small package for improving bowel movement.
- the present invention will be described in more detail with reference to Examples and Test Examples, but these do not limit the present invention.
- dextrin trade name: Fibersol 2H, Matsutani Chemical Industry Co., Ltd.
- Dextrin (trade name: Fiber Monosol 2H, Matsutani Chemical Industry Co., Ltd.) 30 g, xylitol 4 g, and sorbitol 6 g are mixed and sealed in a water-impermeable film bag. One of these packages is to be taken after dissolving in 1 L of water.
- Reduce sodium salt 1.44 g, salt sodium potassium 0.74 25 g, sodium hydrogen carbonate 1.685 g, anhydrous sodium sulfate 5.685 g
- Dextrin (trade name: Fibersol 2H, Matsutani Chemical Industry Co., Ltd.) 20 g, 4 g of xylitol and 7 g of sorbitol are mixed and sealed in a water-impermeable film bag. One of these packages is for dissolving in 1 L of water and used for moonlit.
- Example 10 Oral Intestinal Environmental Conditioning Agent Containing Useful Intestinal Bacterial Growth Promoter
- Example 1 Intestinal Useful Bacterial Composition—1
- Example 1 Intestinal Useful Bacterial Composition 1 2 Bifidobacterium 0.9 g of starch and a small amount of sweetener and flavor were mixed with 0.1 g of dried powder of a culture containing l.Oxl 0 1Q bifidum, and the mixture was sealed in a water-impermeable film bag.
- Bifidobacterium drying the de bacterin Riu arm bifidum 1.0 X 10 1 () pieces cultures containing powder 0.1 g, dry powder 0.1 g of the Enterokodzukasu Fueshiumu 4.0 X 10 g pieces cultures containing Lactobacillus Kazi a 4.0 X 10 9 0.7 g of starch, a trace amount of a sweetener and a flavor were mixed with 0.1 g of the dry powder of the culture containing the cells, and the mixture was sealed in a water-impermeable film bag.
- a small amount of brown sugar and rock salt was added to 1.5 g of agar, 1.5 g of soybean yellow flour, and 0.5 g of apple fiber, and 3.9 g per package was sealed in a water-impermeable film bag.
- Example 1 One package of the oral intestinal environment-regulating agent of Example 1 was packaged with 43 packages of the useful enteric bacteria composition of Example 11 (three days, 4 weeks) and the useful bacteria of Example 14
- An oral normal intestinal bacterial flora development kit was prepared by combining 85 proliferating agent packages.
- Example 1 One package of the oral intestinal environment-regulating agent of Example 1 was packaged with 43 packages of the useful enteric bacteria composition of Example 11 (3 for 4 weeks) and the useful bacteria of Example 14 Combined with 85 growth-promoting agent packages to further improve bowel movement, 1 Z 10 in Example 1 (For preparation of a 20 OmL solution) were combined with each other to prepare an oral normal intestinal bacterial flora growth kit.
- Example 9 One package of the oral intestinal environment-regulating agent of Example 9 was used as a package of the useful enteric bacteria composition of Example 11 4 3 (3 per day, for 4 weeks) and Example 14 Combination of 85 packages of useful intestinal microbial growth promoter was used as an oral normal intestinal flora growth kit.
- Example 1 One package of the oral intestinal environment-regulating agent of Example 9 was packaged with one package of the useful intestinal microbial composition of Example 11 4 3 (3 per day for 4 weeks) and the package of Example 14 Combined with 8 5 packages of useful intestinal bacterial growth promoter, 5 packets containing 1/10 amount of Example 19 (for preparing 20 OiL solution) were used to improve bowel movement. Combined with the kit, an oral normal intestinal flora growth kit was prepared. Test example
- Group B received the useful intestinal bacteria composition of Example 11 and the agent for promoting useful intestinal bacteria of Example 14 in the same manner as in Group A, except that the oral intestinal environmental conditioner was not taken.
- the first day (before taking the oral intestinal environmental conditioner), the second day, the third day, the 14th day, the 21st day, and the 28th day, the stool is collected before or after breakfast.
- 1 g of feces was serially diluted 10-fold with sterile phosphate buffer, and each dilution was spread on an agar plate medium.
- the cells were cultured at 37 ° C for 48 hours by anaerobic culturing with steel wool or anaerobic culturing with carbon dioxide, and the viable bacterial counts of bifidobacterium, lactobacilli, eubacterium, enterococcus, and clostridium were measured.
- FIG. 1 is a graph showing changes in the harmful bacteria rate measured in the test examples. m m
- the oral intestinal environmental conditioner of the present invention can create an environment suitable for the growth of useful bacteria except for intestinal harmful bacteria without imposing an excessive burden on the living body.
- the useful intestinal bacterial composition and the intestinal useful bacterial growth promoter together, it is possible to change the intestinal flora to a favorable intestinal bacterial flora, in which the useful bacteria are predominant and the harmful bacteria are inferior.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005504737A JPWO2004067037A1 (ja) | 2003-01-30 | 2004-01-29 | 経口腸内環境調整剤および経口正常腸内細菌叢育成キット |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003021610 | 2003-01-30 | ||
JP2003-021610 | 2003-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004067037A1 true WO2004067037A1 (ja) | 2004-08-12 |
Family
ID=32820661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/000798 WO2004067037A1 (ja) | 2003-01-30 | 2004-01-29 | 経口腸内環境調整剤および経口正常腸内細菌叢育成キット |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2004067037A1 (ja) |
WO (1) | WO2004067037A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010226994A (ja) * | 2009-03-26 | 2010-10-14 | Q P Corp | 大腸内視鏡検査用食品 |
JP2012102036A (ja) * | 2010-11-09 | 2012-05-31 | Hymo Corp | 便通改善用組成物及びそれを含有する飲食品およびその使用方法 |
CN112167639A (zh) * | 2020-09-29 | 2021-01-05 | 龚代银 | 一种双向调节晨起肠道液体平衡的组合物、制备方法及其用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0225424A (ja) * | 1988-07-13 | 1990-01-26 | Morishita Pharmaceut Co Ltd | 腸管洗浄液用組成物と腸管洗浄液 |
JPH02289520A (ja) * | 1989-02-09 | 1990-11-29 | Hayashibara Biochem Lab Inc | ビフィズス菌増殖促進剤 |
JPH03151854A (ja) * | 1989-11-10 | 1991-06-28 | Calpis Food Ind Co Ltd:The | 腸内有害腐敗産物低減剤 |
JPH03284620A (ja) * | 1990-01-30 | 1991-12-16 | Otsuka Pharmaceut Factory Inc | 腸管洗浄用組成物 |
JPH0638707A (ja) * | 1992-04-10 | 1994-02-15 | Otsuka Pharmaceut Co Ltd | 腸内腐敗産物生成抑制食品組成物 |
JP2000139451A (ja) * | 1998-11-04 | 2000-05-23 | Kao Corp | 腸内酪酸菌生育促進剤 |
JP2000143519A (ja) * | 1998-11-04 | 2000-05-23 | Kao Corp | 腸内低級脂肪酸生成促進剤 |
JP2002275076A (ja) * | 2001-03-15 | 2002-09-25 | Toyo Shinyaku:Kk | 血糖上昇抑制剤および健康食品 |
-
2004
- 2004-01-29 JP JP2005504737A patent/JPWO2004067037A1/ja active Pending
- 2004-01-29 WO PCT/JP2004/000798 patent/WO2004067037A1/ja active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0225424A (ja) * | 1988-07-13 | 1990-01-26 | Morishita Pharmaceut Co Ltd | 腸管洗浄液用組成物と腸管洗浄液 |
JPH02289520A (ja) * | 1989-02-09 | 1990-11-29 | Hayashibara Biochem Lab Inc | ビフィズス菌増殖促進剤 |
JPH03151854A (ja) * | 1989-11-10 | 1991-06-28 | Calpis Food Ind Co Ltd:The | 腸内有害腐敗産物低減剤 |
JPH03284620A (ja) * | 1990-01-30 | 1991-12-16 | Otsuka Pharmaceut Factory Inc | 腸管洗浄用組成物 |
JPH0638707A (ja) * | 1992-04-10 | 1994-02-15 | Otsuka Pharmaceut Co Ltd | 腸内腐敗産物生成抑制食品組成物 |
JP2000139451A (ja) * | 1998-11-04 | 2000-05-23 | Kao Corp | 腸内酪酸菌生育促進剤 |
JP2000143519A (ja) * | 1998-11-04 | 2000-05-23 | Kao Corp | 腸内低級脂肪酸生成促進剤 |
JP2002275076A (ja) * | 2001-03-15 | 2002-09-25 | Toyo Shinyaku:Kk | 血糖上昇抑制剤および健康食品 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010226994A (ja) * | 2009-03-26 | 2010-10-14 | Q P Corp | 大腸内視鏡検査用食品 |
JP2012102036A (ja) * | 2010-11-09 | 2012-05-31 | Hymo Corp | 便通改善用組成物及びそれを含有する飲食品およびその使用方法 |
CN112167639A (zh) * | 2020-09-29 | 2021-01-05 | 龚代银 | 一种双向调节晨起肠道液体平衡的组合物、制备方法及其用途 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004067037A1 (ja) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6985231B2 (ja) | プレバイオティクスとしての、精製された2’−フコシルラクトース、3−フコシルラクトース、およびラクトジフコテトラオースの使用 | |
Chow | Probiotics and prebiotics: a brief overview | |
JP6205003B2 (ja) | 腸内微生物叢バランス及び健康を促進するための栄養組成物 | |
CN1731938B (zh) | 益生元组合物 | |
Parracho et al. | Probiotics and prebiotics in infant nutrition | |
Velázquez et al. | E¡ ect of Oligosaccharides and Fibre Substitutes on Short-chain Fatty Acid Production by Human Faecal Microflora | |
Bosscher et al. | Inulin and oligofructose as prebiotics in the prevention of intestinal infections and diseases | |
ES2268226T3 (es) | Basterias bifidobacterium longun y preparaciones que las contienen. | |
RU2469558C2 (ru) | Применение пробиотиков и волокон при диарее | |
US20100166721A1 (en) | Probotic compositions and uses thereof | |
CN106619743A (zh) | 一种具有降血糖作用的益生菌固体饮料及其制备方法 | |
US20040086491A2 (en) | Probiotic/Prebiotic Composition and Delivery Method | |
US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
ES2320988T3 (es) | Metodo para prevenir o aliviar los sintomas de malabsorcion a traves del tracto gastrointestinal. | |
BRPI0314060B1 (pt) | composição compreendendo variante ou componente de variante de lactobacillus fermentum e usos da variante ou componente de variante de lactobacillus fermentum e da composição | |
CA3138520C (en) | Probiotic bacterial strains that produce short chain fatty acids and compositions comprising same | |
WO2007043563A1 (ja) | 腸内フローラ改善用組成物 | |
CN108753677A (zh) | 一种益生菌的培养方法及其应用 | |
CN113854360A (zh) | 一种益生菌冻干粉及其制备方法 | |
CN112370470A (zh) | 一种重建肠道微生态的微生态制剂 | |
WO2019153334A1 (zh) | 一种调节人体肠道功能的复合益生元及其应用 | |
JP2816726B2 (ja) | 腸内環境改善用組成物 | |
Suarez et al. | An understanding of excessive intestinal gas | |
Sabater-Molina et al. | Effects of fructooligosaccharides on cecum polyamine concentration and gut maturation in early-weaned piglets | |
CN104780788A (zh) | 多糖用于护理的婴儿和/或婴儿的肠道健康的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005504737 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |